ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,10179
0,58%
Bitcoin
63.731,81
-0,25%
Brent Oil
82,765
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Galmed Pharmaceuticals Ltd (GLMD)

  7. Galmed Pharmaceuticals Ltd (GLMD) Notícias

GLMD

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GLMD
DataHoraFonteTítuloCódigoCompanhia
04/04/202418:06PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
15/03/202410:00PR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/02/202416:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
30/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/11/202318:48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202318:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202318:32PR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202309:30PR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/09/202317:05PR Newswire (US)Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202308:30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/07/202311:12Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
18/07/202310:23Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/07/202310:30PR Newswire (US)Galmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingNASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/07/202318:08Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202309:00PR Newswire (US)Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202309:41Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202309:40Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202309:38Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
16/06/202317:17Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/06/202309:14Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/06/202309:00PR Newswire (US)Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
09/05/202308:00PR Newswire (US)Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
29/03/202318:00PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022NASDAQ:GLMDGalmed Pharmaceuticals Ltd
29/03/202317:32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
08/02/202310:00PR Newswire (US)Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine SaltNASDAQ:GLMDGalmed Pharmaceuticals Ltd
04/01/202310:00PR Newswire (US)Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/12/202219:00PR Newswire (US)Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price RequirementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
17/11/202208:25TipRanksH.C. Wainwright Remains a Hold on Galmed Pharmaceuticals (GLMD)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
08/08/202207:25TipRanksH.C. Wainwright Keeps Their Hold Rating on Galmed Pharmaceuticals (GLMD)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
04/08/202209:00PR Newswire (US)Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:GLMD

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZEV4
AZEVEDO PN
BOV
HETA4
HERCULES PN
BOV
AZUL4
AZUL PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados